|
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigation |
1 Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2 Department of Radiology, Toyota Memorial Hospital, Toyota, Japan; 3 Department of Radiological Technology, Nagoya University School of Health Sciences, Nagoya, Japan; 4 Department of Radiology, Fujita Health University School of Health Science, Toyoake, Japan; and 5 Department of Radiology, Nagoya University Hospital, Nagoya, Japan
Correspondence: For correspondence or reprints contact: Katsuhiko Kato, MD, PhD, Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: katokt{at}med.nagoya-u.ac.jp
We compared the efficacies of 18F-FDG PET and 99mTc-bone scintigraphy for the detection of bone metastases in patients with differentiated thyroid carcinoma (DTC). Methods: We examined 47 patients (32 women, 15 men; mean age ± SD, 57.0 ± 10.7 y) with DTC who had undergone total thyroidectomy and were hospitalized to be given 131I therapy. All patients underwent both whole-body 18F-FDG PET and 99mTc-bone scintigraphy. The skeletal system was classified into 11 anatomic segments and assessed for the presence of bone metastases. Bone metastases were verified either when positive findings were obtained on >2 imaging modalities201Tl scintigraphy, 131I scintigraphy, and CTor when MRI findings were positive if vertebral MRI was performed. Results: Bone metastases were confirmed in 59 of 517 (11%) segments in 18 (38%) of the 47 study patients. The sensitivities (visualization rate) for bone metastases on a segment basis using 18F-FDG PET and 99mTc-bone scintigraphy were 50 of 59 (84.7%) and 46 of 59 (78.0%), respectively; the difference between these values was not statistically significant. There were only 2 (0.4%) false-positive cases in a total of 451 bone segments without bone metastases when examined by 18F-FDG PET, whereas 39 (8.6%) were false-positive when examined by 99mTc-bone scintigraphy. Therefore, the specificities of 18F-FDG PET and 99mTc-bone scintigraphy were 449 of 451 (99.6%) and 412 of 451 (91.4%), respectively; the difference between these values was statistically significant (P < 0.001). The overall accuracies of 18F-FDG PET and 99mTc-bone scintigraphy were 499 of 510 (97.8%) and 458 of 510 (89.8%), respectively; the difference between these was also statistically significant (P < 0.001). Conclusion: The specificity and the overall accuracy of 18F-FDG PET for the diagnosis of bone metastases in patients with DTC are higher than those of 99mTc-bone scintigraphy, whereas the difference in the sensitivities of both modalities is not statistically significant. In comparison with 99mTc-bone scintigraphy, 18F-FDG PET is superior because of its lower incidence of false-positive results in the detection of bone metastases of DTC.
Key Words: bone metastases differentiated thyroid carcinoma 99mTc-bone scintigraphy 18F-FDG PET
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hindie, P. Zanotti-Fregonara, I. Keller, F. Duron, J.-Y. Devaux, M. Calzada-Nocaudie, E. Sarfati, J.-L. Moretti, P. Bouchard, and M.-E. Toubert Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome Endocr. Relat. Cancer, September 1, 2007; 14(3): 799 - 807. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |